<DOC>
	<DOC>NCT00291915</DOC>
	<brief_summary>Evaluation of two treatment modalities in early potentially severe early arthritis ( Methotrexate alone or in combination with adalimumab)</brief_summary>
	<brief_title>Multicenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis</brief_title>
	<detailed_description>Patients: early ( less than 6 months), active ( DAS&gt;5.2),potentially severe ( Leiden score&gt;6) Study design:12 months, prospective , randomized, open Study treatments: Methotrexate at a weekly dose of 0.3mg/kilo alone or in combination with adalimumab 40 mg every the other week Outcome measures: DAS over the 12 months</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Early Active Potentially severe arthritis contra indication of methotrexate or anti TNF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>early arthritis, methotrexate, adalimumab</keyword>
</DOC>